EGFR and lung adenocarcinoma: In particular, the ADAURA study demonstrated a significant benefit in terms of disease free-survival (DFS) and overall survival (OS) in the use of the EGFR receptor tyrosine kinase inhibitor osimertinib in the adjuvant setting, in resected lung adenocarcinoma patients with activating mutations in exons 19 and 21 of the EGFR gene [6].